Skip to main content
OpenTrials
Completed

NCT Number: NCT01590784

Reliability and Validity of Thai Calgary Depression Scale of Schizophrenia (CDSS)

Depression in patients with schizophrenia is common. Several factors was found to be associated with depression including medical illness, quality of life, positive symptoms, and typical antipsychotics. The Calgary depression scale of schizophrenia (CDSS) is commonly used for screening depression in schizophrenia,however; the Thai version of CDSS has not been validated.

This study aims to a.) test the reliability and validity of the Thai version of Calgary depression scale of schizophrenia (CDSS) and b.) identify the prevalence and factors associated with depression in patients with schizophrenia including quality of life, type of antipsychotic drugs, and severity of schizophrenia in 60 patients with schizophrenia at the Faculty of Medicine, Chiang Mai University, Thailand.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Depression Behavior Behavioral Symptoms Mental Disorders Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Chiang Mai University

Chiang Mai, 50200, Thailand

About this study

Measurements:

The Thai version of Calgary depression scale of schizophrenia (CDSS), Positive and Negative Syndrome Scale (PANSS), Hamilton Rating Scale for Depression-17 (HAM-D 17), Montgomery-Asberg Depression Rating Scale (MADRS), the Thai abbreviated version of World Health Organization quality of life (WHOQOL-BREF-THAI).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18 years or over
  • Diagnosis of schizophrenia according to DSM-IV-TR

Exclusion criteria

  • Having organic brain syndrome
  • Not fluent in Thai

Treatment and study plan

Primary outcomes

  1. The reliability of the Thai version of the Calgary Depression Scale for Schizophrenia (CDSS) in schizophrenia patients.

    Time frame: 3 months

    The inter-rater reliability, the test-retest reliability will be analyzed.

  2. The validity of the Thai version of the Calgary Depression Scale for Schizophrenia (CDSS) in schizophrenia patients.

    Time frame: 3 months

    The Positive and Negative Syndrome Scale (PANSS), Hamilton Rating Scale for Depression-17 (HAM-D 17), Montgomery-Åsberg Depression Rating Scale (MADRS) will be administered by the first rater, whereas the CDSS will be assessed by a second independent rater.

Secondary outcomes

  1. The prevalence of depression in patients with schizophrenia

    Time frame: 3 months

    The point prevalence of depression in patients with schizophrenia will be presented in percentage.

  2. The association between depression in schizophrenia and quality of life.

    Time frame: 3 months

    The association between depression in schizophrenia and quality of life (WHOQOL-BREF-THAI).

  3. The association between depression in schizophrenia and type of antipsychotic drugs.

    Time frame: 3 months

    The association between depression in schizophrenia and type of antipsychotic drugs (typical vs atypical).

  4. The association between depression in schizophrenia and severity of schizophrenia.

    Time frame: 3 months

    The association between depression in schizophrenia and severity of schizophrenia (PANSS score).

Sponsors and collaborators

Lead sponsor

Chiang Mai University

Other

Registry information

Official study title

The Reliability and Validity of the Thai Version of Calgary Depression Scale for Schizophrenia (CDSS)

Important dates

Study start
2012
Primary completion
2014
Study completion
2014
First posted
May 3, 2012
Registry last updated
Jul 28, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.